Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing AD04, a treatment for alcohol use disorder (AUD) that leverages genetic screening to identify suitable patients. With a significant market opportunity, Adial aims to address the needs of approximately 30 million U.S. individuals with AUD. The company is advancing its clinical trials and regulatory strategy, emphasizing a novel approach that allows for controlled drinking without requiring abstinence.
This description was generated via AI from an annual report. Updated about 1 year ago.